Comparison between Asston Pharmaceuticals IPO and Satol Chemicals IPO.
Asston Pharmaceuticals IPO is a SME Fixed Price IPO proposed to list at BSE SME while Satol Chemicals IPO is a SME Fixed Price proposed to list at BSE SME.
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Sobhagya Capital Options Pvt.Ltd. | Finshore Management Services Ltd. |
| Registrar | Maashitla Securities Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | JSK Securities & Services Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Asston Pharmaceuticals IPO is up to ₹26.17 Cr whereas the issue size of the Satol Chemicals IPO is up to ₹30.24 Cr. The final issue price of Asston Pharmaceuticals IPO is ₹123.00 per share and of Satol Chemicals IPO is ₹72.00 per share.
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹115.00 per share | |
| Issue Price (Upper) | ₹123.00 per share | |
| Issue Price (Final) | ₹123.00 per share | ₹72.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | 1600 shares |
| Fresh Issue Size | 21,28,000 shares | 42,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹26.17 Cr | up to ₹30.24 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 21,28,000 shares | 42,00,000 shares |
| Issue Size Total (Amount) | up to ₹26.17 Cr | up to ₹30.24 Cr |
Asston Pharmaceuticals IPO opens on Jul 09, 2025, while Satol Chemicals IPO opens on . The closing date of Asston Pharmaceuticals IPO and Satol Chemicals IPO is Jul 11, 2025, and , respectively.
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | |
|---|---|---|
| Anchor Bid Date | Jul 08, 2025 | |
| Issue Open | Jul 09, 2025 | |
| Issue Close | Jul 11, 2025 | |
| Basis Of Allotment (Tentative) | Jul 14, 2025 | |
| Initiation of Refunds (Tentative) | Jul 15, 2025 | |
| Credit of Share (Tentative) | Jul 15, 2025 | |
| Listing date (Tentative) | Jul 16, 2025 | |
| Anchor Lockin End date 1 | Aug 13, 2025 | |
| Anchor Lockin End date 2 | Oct 12, 2025 |
Asston Pharmaceuticals IPO P/E ratio is 17.83, as compared to Satol Chemicals IPO P/E ratio of 14.55.
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Asston Pharmaceuticals Limited Financial Information (Restated)Asston Pharmaceuticals Limited's revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| Satol Chemicals Limited Financial Information (Restated Standalone)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 68.76 | 99.98 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 50.66 | 72.63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 17.83 | 14.55 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹104.70 Cr. | ₹110.56 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.56% | 106% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 51.25% | 47.07% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.68 | 1.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.90 | ₹4.95 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 40.36% | 69.28% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Asston Pharmaceuticals IPO Retail Individual Investors (RII) are offered 7,46,000 shares while in Satol Chemicals IPO retail investors are offered 7,46,000 shares. Qualified Institutional Buyers (QIB) are offered 4,25,000 shares in Asston Pharmaceuticals IPO and in Satol Chemicals IPO.
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | |
|---|---|---|
| Anchor Investor Reserveration | 6,35,000 shares | |
| Market Maker Reserveration | 1,13,000 shares | 2,11,200 shares |
| QIB | 4,25,000 shares | |
| NII | 3,22,000 shares | |
| RII | 7,46,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 21,28,000 shares |
Asston Pharmaceuticals IPO subscribed 186.55x in total, whereas Satol Chemicals IPO subscribed .
| Asston Pharmaceuticals IPO | Satol Chemicals IPO | |
|---|---|---|
| QIB (times) | 85.76x | |
| NII (times) | 353.14x | |
| Big NII (times) | 424.47x | |
| Small NII (times) | 210.85x | |
| RII (times) | 172.06x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 186.55x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
